

*Curriculum Vitae*  
**Cecilia C. LOW WANG, MD, FACP**

**Current Positions**

- 2019-present *Professor of Medicine*, Division of Endocrinology, Metabolism & Diabetes,  
Department of Medicine, University of Colorado School of Medicine, Aurora, CO
- 2014-present *Director*, Glucose Management Team, University of Colorado Hospital, Aurora, CO
- 2018-present *Clinician-Scientist*, CPC Clinical Research
- 2019-present *Director*, University of Colorado Diabetes Fellowship Program, Aurora, CO

**Work Address**

University of Colorado School of Medicine  
Anschutz Medical Campus  
Department of Medicine  
Division of Endocrinology, Metabolism, Diabetes  
MS8106, RC-1 South 7103  
12801 East 17<sup>th</sup> Avenue  
Aurora, CO 80045  
(Office) 303.724.7801 (Fax) 303.724.3920  
(Pager) 303.266.0482  
e-mail: [Cecilia.LowWang@CUAnschutz.edu](mailto:Cecilia.LowWang@CUAnschutz.edu)

**Alternate Work Address**

CPC Clinical Research  
2040 N Scranton Street, Suite 2040  
Aurora, CO 80045  
Phone 303.860.9900  
Fax 303.806.1288  
e-mail: [Cecilia.LowWang@CPCMed.org](mailto:Cecilia.LowWang@CPCMed.org)

**Personal Data**

**Place of Birth:** Texas

**Citizenship:** United States of America

**Former Names:** Cecilia C. L. Wang, Cecilia C. Low

**Languages:** English (native speaker), Mandarin Chinese (spoken and written language proficiency)

**Education**

- 1982-1984 W. T. Woodson High School, Fairfax, VA
- 1984-1987 Diploma, Taiwan Provincial Tainan Girls' Senior High School, Tainan, Taiwan
- 1987-1991 Bachelor of Arts *with Distinction in Chemistry*. Senior Thesis passed with Distinction.  
Pomona College, Claremont, CA
- 1991-1996 Doctor of Medicine *with Distinction in Research*. University of Rochester School of  
Medicine, Rochester, NY

**Postgraduate Training**

- 1996-1999 *Intern and Resident*, Department of Internal Medicine, University of Utah Health  
Sciences Center, Salt Lake City, UT
- 1999-2000 *Chief Resident in Internal Medicine*, Department of Internal Medicine, University of  
Utah Health Sciences Center, Salt Lake City, UT
- 2000-2003 *Endocrinology Fellow*, Division of Endocrinology, Metabolism & Diabetes, Department  
of Medicine, University of Colorado Health Sciences Center, Denver, CO

### **Academic Appointments**

- 2003-2004 , *Instructor of Medicine*, Division of Endocrinology, Metabolism & Diabetes, Department of Medicine, University of Colorado Health Sciences Center, Denver, CO
- 2004-2012 , *Assistant Professor of Medicine*, Division of Endocrinology, Metabolism & Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, CO
- 2004-2019 , *Director*, Housestaff and Student Education, Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, CO
- 2006-present , *Faculty*, Medical Education Resources, Littleton, CO
- 2008-2018 , *Associate Director of Fellowship/Education Programs*, Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, CO
- 2012-2019 , *Associate Professor of Medicine*, Division of Endocrinology, Metabolism & Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, CO
- 2019-present , *Professor of Medicine*, Division of Endocrinology, Metabolism & Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, CO

### **Hospital Appointments**

- 2003-2016 *Staff Physician*, Denver Veterans Affairs Medical Center, Denver, CO
- 2003-present *Physician* (Internal Medicine, Endocrinology), University of Colorado Hospital, Aurora, CO
- 2009; 2012-present *Physician*, University of Colorado Hospital Glucose Management Team, Aurora, CO
- 2014-present *Director*, Glucose Management Team, University of Colorado Hospital, Aurora, CO
- 2016-2018 *Physician*, Aspen Valley Hospital, Aspen, CO

### **CPC Clinical Research, Aurora, CO**

- 2013-present *Medical Safety Officer*, Department of Scientific and Medical Affairs
- 2016-present *Safety Lead*, Department of Scientific and Medical Affairs
- 2018-present *Clinician-Scientist*, Department of Scientific and Medical Affairs

### **Government**

- 2016-2020 , *Voting Member*, Endocrinologic and Metabolic Drugs Advisory Committee, U.S. Food and Drug Administration, Silver Spring, MD

### **Research Roles**

- 1988 , *Research Assistant*, Protein chemistry, Department of Biochemistry, National Cheng Kung University Medical College, Tainan, Taiwan
- 1988-1989 , *Laboratory Assistant*, Plant physiology, Department of Biology, Pomona College, Claremont, CA
- 1989 , *Research Assistant*, Medicinal organic chemistry, Department of Chemistry, Pomona College, Claremont, CA
- 1990 , *Research Fellow*, Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
- 1992 & 1993 , *Graduate Student*, Neuroimmunology and aging, Department of Neurobiology and Anatomy, University of Rochester School of Medicine, Rochester, NY

- 1994-1995 , Honors Medical Student Fellow, Diabetes and metabolism, Endocrine/Metabolism Unit, Department of Medicine, University of Rochester School of Medicine, Rochester, NY
- 2001-2012 Please see completed research funding section below
- 2014-2017 Medical Safety Officer: A phase II multicenter, randomized, double-blind, controlled, parallel group study to evaluate the walking time effect of long-term ticagrelor in comparison to long-term aspirin administration in ambulatory patients with peripheral artery disease undergoing endovascular revascularization – The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR.
- 2015-2017 , Medical Safety Officer: A multicenter, randomized, single-blind study with an open-label extension option to further evaluate the safety and efficacy of cryopreserved human amniotic membrane for the treatment of chronic diabetic foot ulcers
- 2016-present , Medical Monitor: Clinical effectiveness of conventional versus X-treated apheresis platelets in patients with hypoproliferative thrombocytopenia
- 2016-2020 , Clinical trial physician for 24-hour helpline: An international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures
- 2017-2020 , International Clinical Adjudication Committee member: An international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures
- 2017-present , Medical Safety Officer: A Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of X for the Treatment of Chronic Venous Leg Ulcers
- 2018-present Lead Principal Investigator: Phase 1 open-label safety study of X to heal chronic diabetic foot ulcers
- 2020-present Principal Investigator: Virta Intervention in CommuniTies in cOloRado (VICTOR-Pilot) Pilot Program to Improve Diabetes and Cardiovascular Risk in Rural Communities
- 2020-present Clinical Endpoint Committee member: NAPc2-201 and NAPc2-301 Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN-COVID-19)

### **Completed/Closed Investigator-Initiated Funded Research**

- Oct 2010-Sep 2012 , Principal Investigator  
Regulation of Egr-1 in Insulin Resistance  
Extension, Career Development Award-2, Department of Veterans Affairs Office of Research and Development, Medical Research Service, Washington, D.C.
- May 2010-Dec 2011 , Co-Investigator  
Adiponectin as an independent determinant of ethnic differences in insulin resistance  
Clinical Translational Research Center study support, CTRC 6149UCH  
National Institutes of Health National Center for Research Resources  
1UL1RR025780

- Oct 2007-Sep 2010 , Principal Investigator  
Regulation of Egr-1 in Insulin Resistance  
Career Development Award-2, Department of Veterans Affairs Office of  
Research and Development, Medical Research Service, Washington, D.C.
- Oct 2004-Sep 2007 , Principal Investigator  
Insulin Resistance and Vascular Disease  
Research Career Development Award, Department of Veterans Affairs Office of  
Research and Development, Medical Research Service, Washington, D.C.
- Jul 2004-Jun 2006 , Principal Investigator  
Diabetes Trust Foundation Clinical Scholars in Diabetes Fellowship.
- Jul 2002-Sep 2004 , Principal Investigator  
Mechanism of the Mitogenic Influence of Hyperinsulinemia  
Associate Investigator Program, Medical Research Service, Veterans Health  
Administration, Department of Veterans Affairs, Washington, D.C.
- Jul 2001 – Jun 2002 , Research Fellow  
Endocrinology, NIH Training Program Grant 5T32DK007446-22, Division of  
Endocrinology, Metabolism and Diabetes, University of Colorado Health  
Sciences Center, Denver, CO.

**Completed/Closed Investigator-Initiated Research (no direct funding)**

- Sep 2015-2018 , Sub-Investigator  
Vitamin D and Type 2 Diabetes Study (D2d)  
ClinicalTrials.gov Identifier: NCT01942694

**Clinical Trial roles (no direct funding)**

- 2007-2013 Safety Monitor - FLARE study (NIH/NIDDK R01) – lipectomy effects on metabolism  
2012-2016 Safety Monitor - Timing Hypothesis for Estrogen Therapy Study (NIH/NIDDK R01)

**Colorado Clinical Translational Science Institute Leadership Innovating in Team Science (LITeS)**

- 2016-2017 , Tenth cohort. Group project: *Catalyzing an Innovation-Entrepreneurship Ecosystem: The Faculty Perspective*. Presented April 7, 2017

**Professional Training**

- 2014-2015 Medical Safety Officer training, CPC Clinical Research  
2016-2017 Leadership Innovating in Team Science (LITeS). Colorado Clinical Translational  
Science Institute.  
2018 Introductory Training Program in Quality Improvement, Institute for Healthcare Quality,  
Safety and Efficiency (IHQSE), University of Colorado Anschutz Medical Campus  
2021 CCTSI Leadership Innovating in Team Science (LITeS) CliftonStrengths Workshop:  
Got Talent? Fostering Great Strengths  
2021 University of Colorado 2020-2021 four-part Equity Certificate Program:  
Unconscious Bias and Virtual Settings, From Bystander to Active Allyship,  
What's in a Name? Equity Concepts, Leading through an Equity Lens.

**Relevant Coursework – University of Colorado Graduate School**

- CLSC 7500 - Practical Application of Molecular and Cell Biology Techniques for the Clinical Investigator (audited 3 credit hr)
- CLSC 7400 – Theory and Application of Techniques for the Study of Human Metabolism *In Vivo* (3 credit hr)
- CLSC 6550 - Applications of Biostatistics to Clinical Research Questions (1 credit hr)

### **Certification**

- State of Colorado Department of Regulatory Agencies Division of Registrations Board of Medical Examiners License for Practice of Medicine: 038877; effective until April 2023
- U.S. Drug Enforcement Administration Controlled Substance Registration Certificate: #BL5553056
- Diplomate*, National Board of Medical Examiners (U.S. Medical Licensing Examination) 1997
- Diplomate* in Internal Medicine. American Board of Internal Medicine 2000
- Diplomate* in Endocrinology, Diabetes and Metabolism. American Board of Internal Medicine 2002, recertified until 2022
- Basic Life Support certification: effective until Feb 2015
- Utah Department of Occupational and Professional Licensing
- Physician and Surgeon: #97-342784-1205; expired Jan 2001 ,
- Controlled Substance: #97-342784-9915; expired Jan 2001 ,

### **Awards and Honors**

- 1987 *International Red Cross Award for Community Service*, Taiwan Chapter
- 1990 *Introduction to Biomedical Research Program*, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
- 1991 , *Stanley D. Wilson Prize in Chemistry*, Pomona College, Claremont, CA
- 1995 , *Distinguished Research Award*, Associated Medical Schools of New York, New York, NY
- 1996 , *Rochester Society of Internal Medicine Prize Award*, Rochester Academy of Medicine, Rochester, NY
- 1996 , *Charles D. Kochakian Award in Endocrinology and Nutrition*, University of Rochester School of Medicine, Rochester, NY
- 1997 , *Outstanding Internal Medicine Intern*, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT
- 1998 , *National Institutes of Health – National Medical Association Clinical Fellowship Travel Award*, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD
- 2001 , *Stanford University Osteoporosis Preceptorship*, Stanford University School of Medicine, Stanford, CA
- 2002 , *Loan Repayment Program for Clinical Researchers*, National Institutes of Health, Bethesda, MD
- 2002 , *Endocrine Fellows Forum and Travel Award*, Endocrine Fellows Foundation and American Diabetes Association, Alexandria, VA (ADA)
- 2002 , *Pfizer Scholars in Endocrinology Award*, Pfizer Inc., New York, NY
- 2003 , *Western Society for Clinical Investigation Travel Award*, American Society for Clinical Investigation, Ann Arbor, MI
- 2003 , *WAFMR/Aventis Scholar*, Western Regional Meeting, American Federation for Medical Research, Manchester, MA
- 2003 , *AstraZeneca Scholarship*, 3<sup>rd</sup> International Workshop on Insulin Resistance, International

- Medical Press, Atlanta, GA
- 2004 *Women in Endocrinology Abstract Award*, Women in Endocrinology, Boston, MA
- 2004 *NIH NIDDK K08 Mentored Clinical Scientist Development Award*: priority score 151. Selected for funding but declined because of simultaneously-awarded other research funding
- 2004 *Clinical Scholars in Diabetes Fellowship*, Diabetes Trust Foundation, Birmingham, AL
- 2005 *Aventis Metabolism Scholar Award*, Western Tri-Societies meeting, American Federation for Medical Research, Manchester, MA
- 2008 *State-of-the-Art Invited Lecture in Metabolism*, Western Tri-Societies meeting, American Federation for Medical Research, Manchester, MA
- 2009 *Fellowship of the American College of Physicians*, American College of Physicians, Philadelphia, PA
- 2009 *Phase I Award*, Novel Clinical and Translational Methods Development Program, Colorado Clinical & Translational Sciences Institute, Aurora, CO
- 2012 *Keynote speaker*, Rocky Mountain Chinese Society for Science and Engineering Annual Meeting, Denver, CO
- 2014 *Symposium speaker*, Italian Society of Diabetology National Meeting, Bologna, Italy. Clinical Symposium entitled “Treatment of the diabetic patient in the hospital”
- 2016 *Master Clinician presenter*, Diabetes, Endocrine Society Annual Meeting 2016, Boston, MA
- 2016-2017 Leadership Innovating in Team Science (LITeS) - Colorado Clinical Translational Science Institute - Tenth cohort. Group project: *Catalyzing an Innovation-Entrepreneurship Ecosystem: The Faculty Perspective*. Presented April 7, 2017

### **Membership in Professional Organizations**

- 1990-2007 , Sigma Xi
- 1999-2000 , *Associates Committee*, American College of Physicians/American Board of Internal Medicine Utah Chapter
- 2001-2013 , American Federation for Medical Research
- 2002-2013 , Women in Endocrinology
- 2003-2004 , *Committee Member*, Basic Research Subcommittee, Research Affairs Committee, Endocrine Society
- 2003-2007 , *Committee Member*, Trainee Development Committee (formerly “Associates Council”), Endocrine Society
- 2004-2007 , *Committee Member*, Clinical Research Subcommittee, Research Affairs Committee, Endocrine Society
- 2005-2013 , American Heart Association
- 2007-2010 , *Committee Member*, Scientific and Educational Programs Core Committee, Endocrine Society
- 2010-2013 , *Committee Member*, Research Affairs Core Committee, Clinical Research Subcommittee, Endocrine Society
- 2016-2017 , *Task Force Member*, Strategic Plan 4 Task Force, Endocrine Society
- 1996-present , American College of Physicians
- 2000-present , Colorado Society for Endocrinology and Metabolism
- 2001-present , Endocrine Society
- 2002-present , American Diabetes Association
- 2004-present , American Association of Clinical Endocrinology
- 2009-present , *Committee Member*, Clinical Diabetes and Endocrinology Annual Conference Program Committee, Clinical Diabetes Endocrine Institute

2009-present *Fellow*, American College of Physicians, Philadelphia, PA

### **Committee and Service Responsibilities**

#### **National**

##### Food and Drug Administration, Silver Spring, MD

2016-2020 *Voting Member*, Endocrinologic and Metabolic Drugs Advisory Committee

2021-present *Chair*, Endocrinologic and Metabolic Drugs Advisory Committee

##### Endocrine Society, Washington, D.C. ,

2003-2004 *Committee Member*, Basic Research Subcommittee, Research Affairs Committee, ,

2003-2007 *Committee Member*, Trainee Development Committee (formerly “Associates Council”), ,

2004-2007 *Committee Member*, Clinical Research Subcommittee, Research Affairs Committee, ,

2007-2010 *Committee Member*, Scientific and Educational Programs Core Committee ,

2010-2013 *Committee Member*, Research Affairs Core Committee, Clinical Research Subcommittee ,

2014-2019 *Committee Member*, Trainee & Career Development Core Committee ,

2016-2017 *Member*, Strategic Plan 4 Task Force ,

2019-present *Committee Member*, Clinical Endocrine Update Steering Committee ,

2021-present *Committee Member At-Large*, Nominating Committee ,

##### American Association of Clinical Endocrinology

2021-present *Chair*, Diabetes Disease State Network

2021-present *Member*, Disease State Network Oversight Committee

#### **School of Medicine**

##### University of Colorado School of Medicine

2004-2006 *Member*, Metabolism Block Subcommittee for development of 2nd year curriculum

2012-2013 *Member*, Advanced Studies (Phase IV) Committee

##### University of Utah School of Medicine

1996-2000 *Member*, Housestaff/Faculty Committee

1997-1999 *Member*, Advisory Committee (for Promotion, Retention and Tenure)

1999-2000 *Member*, Cardiopulmonary Resuscitation Committee

#### **University**

##### Colorado Multiple Institutional Review Board, University of Colorado Anschutz Medical Campus

2006-2007; *Panel Member*, Panel B. *Ad hoc VA representative*, Panel A

2010-2014

Action for Health in Diabetes (Look AHEAD) trial of intensive lifestyle intervention in type 2 diabetes,

Denver, CO site

2007-2013 *Study Physician*

#### **Departmental/Division**

##### Department of Medicine

2004-2009; *Interviewer*, Intern Applicants

2010-2016 ,

2012-2013 *Member*, Morbidity and Mortality Committee, Department of Medicine  
2015-2019 *Member*, Physician Scientist Training Program Selection Committee  
2017-present *Interviewer*, Intern Applicants for Medicine-Pediatrics Housestaff Training Program

Division of Endocrinology, Metabolism, and Diabetes

2008-2011 *Faculty Organizer*, Grand Rounds for Division of Endocrinology, Diabetes and Metabolism  
2008-2018 *Associate Program Director*, Fellowship/Education  
2018-present *Member*, Clinical Leadership Committee

**Hospital**

Denver VA Medical Center, Denver, CO

2008-2010 *Member*, Institutional Animal Care and Use Committee

University of Colorado Hospital, Aurora, CO

2015 *Member*, Access Working Group  
2015-2016 *Member*, JCAHO Inpatient Diabetes Certification Working Group  
2016-present *Member*, Diabetes Advancement Committee

University Physicians Incorporated, Aurora, CO

2016-2017 *Member*, Diabetes Outpatient Workgroup

**Review and Referee Work**

**Grants**

Endocrine Fellows Foundation Fellows Development Research Grant Program in Diabetes, Obesity , and Fat Cell Biology (2011) ,  
American Heart Association Lipids Clinical Committee Grants (2012) ,  
Endocrine Fellows Foundation Marilyn Fishman Grant for Research in Obesity and Type 2 Diabetes , (2013, 2014) ,  
Endocrine Fellows Foundation EFF Endocrine Research Grant (2014, 2015, 2019) ,

**Awards/Funding**

Endocrine Society Lilly Award Grant (2010) ,  
Endocrine Society Early Investigator Award (2011, 2012, 2014, 2015, 2018, 2019, 2020) ,  
Endocrine Society Summer Research Fellowship (2012) ,  
Endocrine Society Clinical Research Fellowship Award in Women's Health (2013) ,  
Endocrine Society Acromegaly Research Fellowship Award (2019) ,

**Abstracts**

*Western Regional Meeting – American Federation for Medical Research* (2008, 2011) ,  
*Endocrine Society ENDO Scientific Sessions – Endocrine Society* (2012, 2013, 2015, 2016, 2018) ,  
*Reducing Health Disparities in Type 2 Diabetes Mellitus Summit –Endocrine Society* (2013) ,  
*University of Colorado Education Innovation Symposium* (2015, 2018) ,  
*International Congress on Endocrinology/Endocrine Society 2014 16th International Congress of'*



*Endocrinology & Endocrine Society's 96th Annual Meeting & Expo* (2014; also judged for the ,  
*Presidential Poster Competition*) ,  
*American Diabetes Association Scientific Sessions* (2016) ,

### **Journals (Ad Hoc)**

*American Journal of Hypertension* (2005-2006) ,  
*Arteriosclerosis, Thrombosis, and Vascular Biology* (2007) ,  
*BMJ Open Diabetes Research & Care* (2019) ,  
*Cardiovascular Diabetology* (2014) ,  
*Circulation* (2013, 2019) ,  
*Clinical Diabetes* (2019) ,  
*Clinical Diabetes and Endocrinology* (2020) ,  
*Clinical Pharmacology & Therapeutics* (2015) ,  
*Diabetes* (2007, 2009) ,  
*Diabetes Care* (2015-present) ,  
*Diabetes Research and Clinical Practice* (2013) ,  
*Diabetes Spectrum* (2013, 2020) ,  
*Diabetologia* (2017-present) ,  
*Endocrine* (2008) ,  
*Endocrine Practice* (2014-present) ,  
*European Journal of Endocrinology* (2011) ,  
*Hospital Practice* (2014) ,  
*Journal of Diabetes Science and Technology* (2015) ,  
*Journal of Hospital Medicine* (2017) ,  
*Journal of the American Heart Association* (2013, 2020) ,  
*Lancet Diabetes and Endocrinology* (2018) ,  
*PLOS One* (2013) ,  
*Vascular Medicine* (2019) ,

### **Editorial Board**

2019-present , Online Resources: Specialty Editorial Board, *Dynamed Plus*. *American College of Physicians Endocrinology Topic Reviewer: Clinical Overviews and Recommendations in Diabetes*.

### **Invited extramural lectures, presentations and visiting professorships**

#### **Local (26)**

- 2003 *Menopause workshop* for Christian Women's Life Changes Seminar, New Jerusalem Missionary Baptist Church, Fountain, CO
- 2005 *Setting Goals*. Diabetes Fall and Spring Conferences, Eastern Colorado Health Care System Denver VA, Denver, CO
- 2006 *Workup for thyrotoxicosis*. Salud Family Clinic, Longmont, CO
- 2006 *Vascular calcification: intersection of bone and vascular biology*. Endocrine Grand Rounds, University of Colorado School of Medicine Department of Medicine Division of Endocrinology, Metabolism and Diabetes, Aurora, CO

- 2006 , *New diabetes agents and their role in type 1 and type 2 diabetes*. University of Colorado Department of Medicine Internal Medicine Update, Estes Park, CO
- 2006 *Making Sense of Your Cholesterol*. Diabetes Fall and Spring Conferences, Eastern Colorado Health Care System Denver VA, Denver, CO
- 2007 , *Insulin effects in vascular smooth muscle cells*. Endocrine and Hormonal Malignancies Research Conference, University of Colorado School of Medicine, Aurora, CO
- 2007 , *The Slippery Slope of Lipid Profiles*. Diabetes Fall and Spring Conferences, Eastern Colorado Health Care System Denver VA, Denver, CO
- 2008 , *Managing hyperglycemia to reduce microvascular complications in type 2 diabetes* (talk and panel discussion). Look AHEAD trial, Denver, CO
- 2008 , *Diabetic neuropathy*. University of Colorado School of Medicine Endocrine Practice Monthly Diabetes Conference, Aurora, CO
- 2008 , *Vitamin D: insulin sensitivity and vascular disease*. University of Colorado Cardiometabolic disease Across the Lifespan (CALM) monthly conference, Aurora, CO
- 2009 , *Diabetic neuropathy – the forgotten complication*. University of Colorado School of Medicine General Internal Medicine Practice Clinical Conference, Aurora, CO
- 2009 , *Lipids: Issues in Diabetes*. Diabetes Fall and Spring Conferences, Eastern Colorado Health Care System Denver VA, Denver, CO
- 2009 , *Diabetic neuropathy*. University of Colorado School of Medicine General Internal Medicine Garfield Clinic Conference, Denver, CO
- 2011 , *Vitamin D and Cardiovascular Disease*. Presbyterian-St. Luke's Hospital Internal Medicine Grand Rounds, Denver, CO
- 2011 , *Vitamin D and Cardiovascular Health: Association or Causation?* University of Colorado School of Medicine Division of Endocrinology Grand Rounds, Aurora, CO
- 2011 , *Molecular mechanisms of vascular dysfunction in a novel porcine model of diet-induced obesity*. VA Research Days, Denver VA Medical Center, Denver, CO
- 2011 , *What a Difference 10 Years Makes! Advances in Diabetes Over the Last 10 Years* (talk and panel discussion). Look AHEAD trial retention event, Denver, CO
- 2012 , *Update – What's Hot in Diabetes* (talk). Look AHEAD trial retention event, Denver, CO
- 2013 , *Eye Health and Retinopathy*. Look AHEAD trial retention event, Denver, CO
- 2014 , *From Aspirin to Insulin*. American Diabetes Association Expo, Denver, CO
- 2014 , *What you need to know about diabetes in 2014*. Colorado Heart Healthy Solutions New Community Health Worker Workshop, Aurora, CO
- 2015 , *Diabetic Ketoacidosis: Innovative Strategies for a Challenging Condition*. University of Colorado School of Medicine Division of Endocrinology Grand Rounds, Aurora, CO
- 2018 , *Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome*. Lecture. Advanced Practice Providers, Medical Intensive Care Unit, University of Colorado Hospital, Aurora, CO
- 2020 , *Diabetes – 2020 Update for Colorado Heart Healthy Solutions*. Colorado Heart Healthy Solutions Community Health Navigator Training Workshop, Aurora, CO
- 2021 , *CoViD-19, Hyperglycemia and Diabetes – What's the Connection?* University of Colorado Endocrinology Division Grand Rounds Co-presenter, Aurora, CO.

### **Regional (21)**

- 2006 , *New diabetes agents and their role in type 1 and type 2 diabetes*. University of Colorado Department of Medicine Internal Medicine Update, Estes Park, CO

- 2006 *Treatment paradigms for diabetes*. Fall 2006 Primary Care Conference of the Community Health Association of Mountain/Plains States and the Northwest Regional Primary Care Association, Denver, CO
- 2007 *New horizons in diabetes treatment*. American Academy of Nurse Practitioners Wyoming Fall Conference, Cheyenne, WY
- 2007 , *Nephropathy and end-stage renal disease in diabetes – Management Issues*. Grand Junction VA Medical Center educational sessions, Grand Junction, CO.
- 2007 , *Making sense of insulin therapy for type 2 diabetes*. Grand Junction VA Medical Center educational sessions, Grand Junction, CO.
- 2008 , *Aortic insulin signaling is perturbed in a large animal model of diet-induced obesity*. State-of-the-Art Invited Lecture in Metabolism: Western Tri-Societies meeting, American Federation for Medical Research, Manchester, MA
- 2008 , Session Chair, Western Tri-Societies Meeting, *American Federation Medical Research*
- 2008 , *Lipids in women* (talk and panel discussion). 6<sup>th</sup> Annual Colorado Women’s Cardiovascular Health Symposium. Center for Women’s Health Research, Denver, CO
- 2012 , *Diabetes – It’s not just about the sugar!* Rocky Mountain Chinese Society of Science and Engineering 30<sup>th</sup> Annual Conference, Denver, CO
- 2013 , *Diabetes and Cardiovascular Disease: Current Data and How to Prioritize Risk Reduction* (talk and panel discussion). 11<sup>th</sup> Annual Colorado Women’s Cardiovascular Health Symposium. Center for Women’s Health Research, Aurora, CO
- 2013 , *Where and How Does Vitamin D Fit into Women’s Health Care?* Colorado Obstetrics and Gynecology Society annual meeting, Denver, CO
- 2014 , *Diabetes and Cardiovascular Risk*. 30<sup>th</sup> Annual Winter CME Meeting, Colorado Academy of Physicians Assistants, Copper Mountain, CO.
- 2015 , *Advanced Insulin Management and Delivery*. American Diabetes Association 3rd Annual Advanced Diabetes Practice for Primary Care conference, Denver, CO
- 2015 , *Type 2 Diabetes*. Family Medicine Forum, Florida Academy of Family Physicians, Palm Beach, FL
- 2015 , *Obesity*. Family Medicine Forum, Florida Academy of Family Physicians, Palm Beach, FL
- 2016 , *Insulin Therapy for Type 2 Diabetes: When and How*. Rocky Mountain Metabolic Syndrome Symposium 2016, Aurora, CO
- 2018 , *Inpatient Diabetes Management*. Diabetes Update for Endocrinology Fellows: Diabetes Dialog. Barbara Davis Center for Diabetes and University of Colorado Anschutz Medical Campus, Aurora, CO.
- 2019 , *Which Treatments for Diabetes? Getting to the “Heart” of the Matter*. 20th Annual Diabetes Conference: Current Treatments for Diabetes Complications. University of Rochester School of Medicine and Dentistry, Rochester, NY.
- 2019 , *Workshop 3: Diabetes and Cardiovascular Disease*. 20th Annual Diabetes Conference: Current Treatments for Diabetes Complications. University of Rochester School of Medicine and Dentistry, Rochester, NY.
- 2019 , *Diabetes Case Presentations – Panel Discussion*. Panelist. 20<sup>th</sup> Annual Diabetes Conference: Current Treatments for Diabetes Complications. University of Rochester School of Medicine and Dentistry, Rochester, NY.
- 2020 , *Diabetes: Putting it all together to design a high value diabetes regimen for your patient*.

American College of Physicians Colorado Chapter Meeting, Colorado Springs, CO.

**National (29)**

- 2003 , Visiting Professor, University of Utah Health Sciences Center, Salt Lake City, UT  
*Insulin and vascular smooth muscle cell phenotype*. Research Seminar, Cardiac and Vascular Biology Group  
*Thyroid emergencies*. Internal Medicine Housestaff noon conference
- 2005 , Co-moderator for Clinical Investigator's Workshop for Trainees, *Endocrine Society*
- 2010 , *Early defects occur in PI3-kinase/Akt signaling and vascular function in a novel porcine model of diet-induced obesity*. American Diabetes Association Scientific Sessions, Orlando, FL
- 2012 , Symposium chair: CVD Risk in Diabetes – Is Glucose Important? *ENDO 2012*, Houston, TX. Endocrine Society.
- 2012 , Session Chair, Clinical Research Fellowship and Mentor Oral Presentation session, *ENDO 2012*, Houston, TX. Endocrine Society.
- 2014 , *Inpatient Hyperglycemia in Select Populations*. Clinical Diabetes and Endocrinology in 2014 Conference, Snowmass, CO
- 2014 , Symposium chair: Diabetes: An Assault on the Vasculature. *16th International Congress of Endocrinology & the Endocrine Society's 96th Annual Meeting & Expo*, Chicago, IL. Endocrine Society.
- 2015 , Co-chair, 2015 Oral Presentations in Reproductive Science Competition, Endocrine Society Annual Meeting 2015
- 2016 , *Management of Hyperglycemia in the Inpatient Setting*. Endocrine Society Annual Meeting Meet the Professor Sessions, Boston, MA
- 2017 , *New Insulin Therapies – Practice Changing?* Clinical Diabetes and Endocrinology 2017 – Snowmass, CO.
- 2017 , Chair, Symposium: *Can We Improve Cardiovascular Risk in Type 2 Diabetes?* Endocrine Society Annual Meeting 2017
- 2017 , Moderator, panel discussion of cases: *Mixed-up Metabolism – Obesity and Lipid Disorders*. Clinical Diabetes and Endocrinology 2017 – Snowmass, CO.
- 2017 , *Insulin Management Algorithms for the Inpatient Setting*. Symposium. American Diabetes Association 77<sup>th</sup> Scientific Sessions, San Diego, CA
- 2017 , *Recurrent DKA – An Approach to a Recurrent Challenge*. Association of Diabetes Centers: PRIDE and PROUD Meeting, American Diabetes Association 77<sup>th</sup> Scientific Sessions, San Diego, CA
- 2018 , *A Balancing Act: Benefits vs Risks of Diabetes Therapies*. Clinical Diabetes and Endocrinology 2018 – Snowmass, CO
- 2018 Moderator, panel discussion of cases: *Complications and Comorbidities: Challenging Diabetes Cases*. Clinical Diabetes and Endocrinology 2018 – Snowmass, CO
- 2018 , *Effective Inpatient Glucose Management Team - Structure and Function*. Planning Research in Inpatient Diabetes (PRIDE) General Session, American Diabetes Association 78<sup>th</sup> Annual Scientific Sessions, Orlando, FL.
- 2019 , Panelist, *Dilemmas in Diabetes Management – Case-Based Panel Discussion*. Colorado Diabetes and Endocrinology Institute 55<sup>th</sup> Annual CME Conference, Snowmass, CO.
- 2019 , Panelist, *Diabetes and Lipid-Lowering - Which Treatment for Which Patient?* In session 763.

- Ambulation to Rivaroxaban: Branching outside the coronaries. American College of Cardiology ACC.19 Scientific Sessions 2019, New Orleans, LA.
- 2019 , Co-Chair, Oral abstract session *OR 28. Metabolism, Diabetes and Obesity: New Mechanisms and Models*. ENDO 2019 Endocrine Society 101<sup>st</sup> Annual Meeting and Expo, New Orleans, LA.
- 2019 , *Cardiovascular and Limb Outcomes in Patients with DM and Peripheral Artery Disease*. 3<sup>rd</sup> Annual Heart in Diabetes. Philadelphia, PA.
- 2020 , Panelist, *Challenges in Diabetes – Case-Based Panel Discussion*. Colorado Diabetes and Endocrinology Institute 56<sup>th</sup> Annual CME Conference, Snowmass, CO.
- 2020 , *Which Therapy for Which Patient? Complexities in Diabetes Management*. Clinical Diabetes and Endocrinology Institute 56<sup>th</sup> Annual CME Conference, Snowmass, CO.
- 2020 , *Managing Risk in Survivors on Androgen Deprivation*. American College of Cardiology ACC.20 Virtual Annual Meeting, Chicago, IL.
- 2020 , *Management of Steroid Associated Hyperglycemia in Inpatient and Outpatient Settings*. Professional Interest Group Discussion on Clinical Centers & Programs - Frequently Encountered Glycemic Management Issues Without Clear Guidelines. American Diabetes Association 80<sup>th</sup> Scientific Sessions, Virtual Meeting.
- 2020 , *Severe Hypoglycemia: The Frequently Forgotten Threat*. Endocrine Society ENDO 2020 Online Meeting. CME MOC Special Program.
- 2020 , *Whose Job Is It? Multidisciplinary Management of Peripheral Artery Disease*. Moderator. Educational panel discussion webinar presented during American Diabetes Association Scientific Sessions (Virtual).
- 2020 , *Lowering Glucose in Older Patients: How Much is Too Much?* Session #: GR.CVS.446, Session Title: Cardiovascular Disease Prevention in Older Adults: Reconciling Recommendations with Reality. American Heart Association 2020 Scientific Sessions (Virtual).
- 2021 , *How Will This Impact FDA Approval of Diabetes Drugs? In Symposium S20: More Than A1c: Important Outcomes for Those With Diabetes*. Endocrine Society ENDO 2021 Annual Meeting (Virtual).

### **International (3)**

- 2014 , *Anti-hyperglycemic therapy in the patient on enteral nutrition*. Symposium speaker, Italian Society of Diabetology National Meeting, Bologna, Italy.
- 2020 , *CoViD-19 and Diabetes: What Have We Learned So Far?* Symposium speaker, National Physicians Association of Zimbabwe NAPAZ Annual Sessions (Virtual).
- 2020 , *Best Medical Therapy to Support Successful Revascularization*. Organizer and panelist, European Society for Vascular Surgery (Virtual).

### **TEACHING RECORD**

#### **High School Students '**

##### **CU Pre-Health Scholars Program (CUPS) '**

- 2021 , Health Disparities in Diabetes. Summer course: Health, Equity and Social Justice. University of Colorado Anschutz Medical Campus, Aurora, CO.

#### **Undergraduate Students**

##### **Dine College, Tsaile, AZ**

- 2010 , Medicine as a career path. Clinical Translational Science Award (CTSA) Education and Training Pillar, Aurora, CO Summer Research Enhancement Program in Cancer and

2010 , Diabetes Prevention. University of Colorado School of Medicine  
NIH Clinical Translational Science Award Education and Training Pillar, University of  
Colorado School of Medicine Aurora, CO. Research presentation advisor for Summer  
Research Enhancement Program in Cancer and Diabetes Prevention

### **Graduate and Medical School Students**

#### **Summer Research Fellowship Webinar, Endocrine Society**

2016, 2017, 2018, 2019 *How to Choose a Good Mentor and Be a Good Mentee.*

### **Graduate School Students**

#### **University of Colorado Health Sciences Center Graduate School**

2006 , RPSC 7801: Endocrinology and Metabolism. *Thyroid function and disease* (1 hr).

2009 , Reproductive Sciences Graduate Program: *“Insulin resistance and diabetes mellitus:  
Clinical correlates”* (1 hr), University of Colorado School of Medicine, Aurora, CO

### **Medical School Students**

#### **University of Utah School of Medicine**

1999-2000 , Morning report 4 days/week, Morbidity and Mortality Conferences 2/month, 3<sup>rd</sup> and  
4<sup>th</sup> year medical student EKG sessions weekly, medical service attending 7.5 weeks.  
Organized departmental Grand Rounds and daily housestaff and medical student noon  
conferences

#### **University of Colorado School of Medicine**

2002-2006 , Gastrointestinal, Endocrine and Metabolism Block small group facilitator (2<sup>nd</sup>-year  
medical students): 12-14 hr/yr

2003-2011 , Ward attending for Medical Service, 2-4 weeks/yr, Denver VA Medical Center

2003-2015 , Consult attending for Endocrine Inpatient Consult Service, 2-6 weeks/yr, University of  
Colorado Hospital and Denver VA Medical Center

2004-2007 , Foundations of Doctoring small group facilitator: abdominal, head and neck, and  
pulmonary exams, cardiovascular risk assessment, and Transition to Third Year oral  
presentations (2<sup>nd</sup>-year medical students)

2006 , Lecturer, Gastrointestinal, Endocrine and Metabolism Block (2<sup>nd</sup> year medical  
Students): *Non-insulin glucose-lowering therapies for diabetes* (1 hr/yr)

2006-2017 , Digestive, Endocrine and Metabolism Block small group facilitator (2<sup>nd</sup> year medical  
students): 4-8 hr/yr

2007-2010 , Life Cycle Block male and female reproductive small group discussions (2<sup>nd</sup> year medical  
students): 2-4 hr/yr

2007-present , Lecturer, Digestive, Endocrine and Metabolism Block (2<sup>nd</sup> yr medical students): *Non-  
insulin therapies for diabetes* (1 hr/yr)

2007-present , Lecturer, Digestive, Endocrine and Metabolism Block (2<sup>nd</sup> yr medical students): *Insulin  
therapy for diabetes* (1 hr/yr)

2008 , Adult Ambulatory Care Clerkship Chronic Disease Experience Subspecialty Preceptor  
for 3<sup>rd</sup> yr medical students

2008 , Lecturer, Digestive, Endocrine and Metabolism Block (2<sup>nd</sup> yr medical students):  
*Pathophysiology of type 2 diabetes* (1 hr)

- 2006 ,           Lecturer, PATH 8001: Interpretive Clinical Pathology (4<sup>th</sup> year medical students).  
*Reproductive endocrinology laboratory testing* (2 hr).
- 2010 ,           Poster judge for Mentored Scholarly Activity Capstone Event (4<sup>th</sup> yr medical students)
- 2012-2015 ,     Ward attending for Internal Medicine Service, 2-4 weeks/yr, University of Colorado  
Hospital
- 2016-present ,   Consult attending for Endocrine Inpatient Consult Service, 4-6 weeks/yr, University of  
Colorado Hospital
- 2016 ,           First Course Health Disparities, Longitudinal Core Curriculum for 1<sup>st</sup> year medical  
students: small group facilitator

### **Housestaff – Internal Medicine**

#### **University of Utah School of Medicine**

- 1999-2000 ,     Morning report 4 days/week, Morbidity and Mortality Conferences 2/month, 3<sup>rd</sup> and  
4<sup>th</sup> year medical student EKG sessions weekly, medical service attending 7.5 weeks.  
Organized departmental Grand Rounds and daily housestaff and medical student noon  
conferences

#### **University of Colorado School of Medicine**

- 2001-2003 ,     Endocrine lectures and problem sessions for housestaff (monthly), Department of  
Medicine
- 2003-2004; 2006-2009; Housestaff Noon Conference: *Glycemic Emergencies*; Also *Inpatient  
Hyperglycemia Management*, Department of Medicine
- 2003-2011 ,     Ward attending for Medical Service with housestaff teams, 2-4 weeks/yr, Denver VA  
Medical Center
- 2013-2015 ,     Ward attending for Medical Service with housestaff teams, 2 weeks/yr, University of  
Colorado Hospital
- 2003-present ,   Consult Attending for Endocrinology Inpatient Consult Service, Department of Medicine
- 2018-2019 ,     Housestaff Noon Conference: *Inpatient Hyperglycemia and Diabetes Management*, 1  
lecture/month, Department of Medicine
- 2020-present ,   Housestaff Noon Conference: *Inpatient Hyperglycemia and Diabetes Management*,  
Department of Medicine

### **Housestaff – Family Medicine**

#### **University of Colorado School of Medicine**

- 2009 ,           *Diabetic neuropathy*. Housestaff Conference. Department of Family Medicine
- 2014-present ,   *Inpatient diabetes/hyperglycemia management*, Family Medicine Housestaff Training  
Program Chautauqua intern lecture series
- 2016-present ,   *Diabetic emergencies*. Family Medicine Housestaff Training Program Chautauqua intern  
lecture series

### **Housestaff and Fellows**

#### **University of Colorado School of Medicine**

- 2003-2015 ,     Consult attending for Endocrine Inpatient Consult Service, 2-4 weeks/yr, University of  
Colorado Hospital and Denver VA Medical Center

- 2013-present Diabetes Clinical Conference, founder and organizer  
2016-present Consult attending for Endocrine Inpatient Consult Service, 4-6 weeks/yr, University of Colorado Hospital  
2019-present *Large Group Lectures*. Residents and Fellows as Educators Elective, Academy of Medical Educators (May 2019, Dec 2019, Dec 2020, May 2021).

### **Interprofessional Education Program Students**

#### **University of Colorado Anschutz Medical Campus**

- 2011-2013 , Facilitator for Interprofessional Education Health Mentors Program – Schools of Medicine, Nursing, Pharmacy, Physician’s Assistant, Physical Therapy, Dentistry

#### **University of Colorado Health Nurses**

- 2016 *Inpatient Glucose Control*, Half-day course for Obstetrics/Gynecology Registered Nurses, University of Colorado Hospital  
2019-present *Inpatient Hyperglycemia and Diabetes Overview*, Half-day course for Registered Nurses, Memorial Hospital, Colorado Springs, CO. Given twice a year.

### **Clinical Fellows, Graduate and Undergraduate Students, Junior and Mid-Career Faculty**

#### **Endocrine Society Annual Meeting Career Development Workshops**

- 2017 *Promotion and Tenure/CV Writing*. ENDO 2017, Orlando, FL  
2018 *Navigating Career Transitions: Lessons Learned as a New PI*. ENDO 2018, Chicago, IL  
2019 *Personal Stories: Careers in Academia*. Career Pathways. ENDO 2019, New Orleans, LA.  
2019 *Leadership Skills Lab: Conflict, Resolution, and Negotiation*. ENDO 2019, New Orleans, LA.  
2020 *Difficult Conversations: Conflict Resolution and Negotiations. The Importance of Framing*. ENDO 2020, Virtual Meeting  
2021 *Let’s Talk: Science, Communication, and Social Media*. ENDO 2021. Professional Development Workshop. On-Demand, workshop number PDW05

#### **Endocrine Society Future Leaders Advancing Research in Endocrinology (FLARE) workshops**

- 2021 , *Demystifying the Job Search and Negotiations*. Virtual.

#### **Endocrine Society Career Development Podcast Series**

- 2019 , *Bouncing Back*. Episode 17 (ENP17). April 29, 2019.  
<https://www.endocrine.org/podcast/enp17-bouncing-back>

### **Clinical Fellows**

#### **American Diabetes Association Focus on the Fellows**

- 2020 , *Keep Your Career Path Options Open*, Panelist. (Virtual)

### **Clinical Research Faculty, Clinical Research Associates and Staff**

- 2015-2016 , *Clinical Trial Design* lecture for Colorado Clinical Translational Science Institute Seminar Series.

### **KEY ADMINISTRATIVE POSITIONS**



**University of Colorado School of Medicine**

- 2004-2019 Director, Education Programs, Housestaff and Medical Students, Endocrinology, Metabolism and Diabetes, Department of Medicine  
2008-2018 Associate Director, Fellowship Program in Endocrinology, Metabolism, and Diabetes, Department of Medicine  
2019-present Director, Fellowship Program in Diabetes, Department of Medicine

**TEACHING SCHOLARS PROGRAM, University of Colorado Anschutz Medical Campus School of Medicine**

- 2013-2014 , Teaching Scholar. Project: *Targeting Educational Gaps in Hospital Management of Diabetes and Stress Hyperglycemia with Resident Education*. Presented at the 2015 University of Colorado Education Innovation Symposium (Feb 2015)

**ACADEMY OF MEDICAL EDUCATORS, University of Colorado Anschutz Medical Campus School of Medicine**

- 2018 Selected for membership  
2021 Co-Chair, Membership Committee

**Mentorship**

**Clinical Fellows**

- Fellowship in Endocrinology, Metabolism, and Diabetes, University of Colorado School of Medicine  
2005-2007 Mentorship committee member for clinical endocrinology fellow.  
Endocrinologist, Denver Endocrinology, Diabetes and Thyroid Center, Englewood, CO  
2007-2009 Mentorship committee member for clinical endocrinology fellow.  
Endocrinologist, New West Physicians, Lakewood, CO  
2010-2012 Mentorship committee member for clinical endocrinology fellow.  
Clinical Investigator, Institute for Health Research, Kaiser Permanente Colorado  
Affiliate Assistant Professor of Medicine, University of Colorado School of Medicine  
2012-2014 Mentorship committee member for clinical endocrinology fellow.  
Endocrinologist, The Austin Diagnostic Clinic, Austin, TX  
2013-2014 Co-mentor for clinical endocrinology fellow.  
Endocrinologist, OhioHealth Endocrinology Physicians, Columbus, OH  
2014-2015 Academic mentor for endocrinology faculty member.  
Endocrinologist, Kaiser Permanente, Honolulu, HI  
2018-2021 Mentorship Committee member for clinical endocrinology fellow.  
University of Colorado School of Medicine  
2019-present Mentorship Committee member for clinical endocrinology fellow.  
University of Colorado School of Medicine
- Fellowship in Pediatric Endocrinology, University of Colorado School of Medicine  
2016-2018 Scholarly Oversight Committee member for pediatric endocrinology fellow.  
Instructor, Department of Pediatrics, University of Colorado School of Medicine  
2018-2021 Scholarly Oversight Committee member for pediatric endocrinology fellow.  
University of Colorado School of Medicine

**Doctor of Nurse Practitioner**

College of Nursing ,

2016-2018      Committee member, Doctor of Nurse Practitioner candidate dissertation.  
Assistant Professor of Medicine, University of Colorado School of Medicine

2017-2018      Co-mentor, Doctor of Nurse Practitioner candidate dissertation.  
Instructor of Medicine, University of Colorado School of Medicine

**Teaching Portfolio available upon request, containing details of educational activities including course development, syllabi, and teaching evaluations**

**Learning Sessions completed – Academy of Medical Educators, University of Colorado SOM**

Dec 17, 2009 , Teaching in the Clinical Setting

Mar 15, 2010 , Public Speaking and PowerPoint Workshop

Apr 23, 2010 , Identification & Remediation of Struggling Students Workshop

Jul 22, 2010 , Mentor/Mentee Workshop

Aug 24, 2010 , Better Bedside Teaching Workshop

Jan 6, 2011 , How to Build a Teacher's Portfolio

April 12, 2011 , Writing Test Questions

May 17, 2011 , Team-Based Learning - Designing Group Work that Really Works  
Team-Based Learning - Getting Beyond Covering Content

Dec 4, 2012 , Designing Clinical Cases for Teaching and Assessment

Jan 29, 2013 , Leading Change

Nov 12, 2013 , Conflict Styles

Dec 6, 2018 , Large Group Lectures

Dec 13, 2018 , Mentorship

**COMMUNITY OUTREACH and CLINICAL LECTURES**

2006-2016 , *Type 1 Diabetes; Type 2 Diabetes; Hyperlipidemia; Management of obesity.* Clinical Endocrinology for Primary Care Physicians, Continuing Medical Education conference, Medical Education Resources, various locations in US: Oct 2006, Nov 2009, Dec 2012, Aug 2014, Jul 2016, Sep 2016

2006-2008 , *Thyroid Disease in Women; Osteoporosis; Management of Obesity; Endocrine Cases.* Issues in Women's Health for Primary Care Physicians, Continuing Medical Education conference, Medical Education Resources conferences, various locations in US: Dec 2006, Apr 2007, Jul 2007, Dec 2007, Jul 2008

2008-2009 , *Type 2 diabetes – update on pathophysiology and treatment; Current management of thyroid disorders; Osteoporosis: recent developments; Case presentations – Endocrinology.* Internal Medicine for Primary Care Physicians, Continuing Medical Education conference, Medical Education Resources, various locations in US and Caribbean: Mar 2008, Mar 2009, Dec 2009

2011-2012 , Eastern Colorado Health Care System SCAN-ECHO: Tele-educational outreach program for care providers within the VISN 19 region. 45 minute lectures and case discussions on endocrine topics, targeted to primary care providers.

Jul 2011      *Chronic kidney disease in diabetes*

Aug 2011      *Clinical management of hypothyroidism*

Sep 2011      *Issues in Vitamin D*

- May 2012      *Osteoporosis*
- 2016 May      *Type 1 diabetes; Type 2 diabetes; Disorders of Calcium Metabolism; Metabolic Bone Disease*. Internal Medicine for Primary Care Physicians, Continuing Medical Education conference, Medical Education Resources, Grand Cayman
- 2016 Jun, Sep      *Type 2 diabetes mellitus; Disorders of Thyroid Function; Osteoporosis; Obesity Management Update*. Internal Medicine for Primary Care Physicians, Continuing Medical Education conference, Medical Education Resources, Las Vegas, Cape Cod
- 2017 May      *Type 2 Diabetes; Insulin Therapy for Diabetes; Management of Dyslipidemia; Obesity Management Update*. Internal Medicine for Primary Care: Endo/Geri/Psych/Rheum, Continuing Medical Education conference, Medical Education Resources, Key West, FL
- 2017 Jul      *Type 2 Diabetes; Insulin Therapy for Diabetes; Management of Dyslipidemia; Obesity Management Update*. Internal Medicine for Primary Care: Cardio/Endo/Neuro/Pulm, Continuing Medical Education conference, Medical Education Resources, Maui, HI
- 2018 Sep.      *Type 2 Diabetes; Insulin Therapy for Diabetes; Thyroid Disease Update; Obesity Management Update*. Internal Medicine for Primary Care: Cardio/ENT/ID/Endo, Continuing Medical Education conference, Medical Education Resources, Maui, HI
- 2019 Feb.      *Osteoporosis, Thyroid Disorders in Women, Obesity Management, Endocrine Cases*. Women's Health for Primary Care: Endo/Gyn/Psych, Medical Education Resources, Las Vegas, NV
- 2021 Jun      *Should metformin remain first-line therapy for type 2 diabetes?* American Heart Association and American Diabetes Association Know Diabetes By Heart podcast.

## BIBLIOGRAPHY

### Publications in Peer-reviewed Journals

- 1) ' King CL, **Low CC**, and Nutman TB. IgE production in human helminth infection: Reciprocal interrelationship between IL-4 and IFN- $\gamma$ . *J Immunol* 1993;150(5):1873-1880. PMID: 8094729.
- 2) ' **Low CC**, Grossman EB, and Gumbiner B. Potentiation of effects of weight loss by monounsaturated fatty acids in obese NIDDM patients. *Diabetes* 1996;45:569-575. PMID: 8621005.
- 3) ' Gumbiner B, **Low CC**, and Reaven PD. Effects of a monounsaturated fatty acid-enriched hypocaloric diet on cardiovascular risk factors in obese patients with type 2 diabetes. *Diabetes Care* 1998;21(1):9-15. PMID: 9538963.
- 4) ' **Wang CCL**, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. *Diabetes* 2003;52:2562-2569. PMID: 14514641.
- 5) ' Hirshman E, Merritt P, **Wang CC**, Wierman M, Budescu DV, Kohrt W, Templin JL, Bhasin S. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. *Horm Behav* 2004;45(2):144-55. PMID: 15019802.

- 6) ' **Wang CC**, Goalstone M, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. *Diabetes* 2004;53:2735-2740. PMID: 15504952.
- 7) ' **Wang CC**, Sharma G, Draznin B. Egr-1 expression in vascular smooth muscle cells: effects of insulin and oxidative stress. *Am J Hyperten* 2006;19(4):366-372. PMID: 16580571.
- 8) ' **Wang CC**, Sorribas V, Sharma G, Levi M, Draznin B. Insulin attenuates vascular smooth muscle calcification but increases vascular smooth muscle cell phosphate transport. *Atherosclerosis* 2007;195:e65-e75. PMID: 17412344.
- 9) ' Reusch JEB, **Wang CC**. Cardiovascular disease in diabetes: Where does glucose fit in? *J Clin Endocrinol Metab* 2011;96:2367-2376. PMID: 21593112.
- 10) Pereira RI, **Wang CC**, Hosokawa P, Dickinson M, Neuman C, Karimkhani E, Erickson C, Chonchol M, Krantz M, Steiner JF, Besessen DH, Havranek EP, Long C. Circulating adiponectin levels are lower in Latino versus non-Latino white patients at risk for cardiovascular disease, independent of adiposity measures. *BMC Endocr Disord* 2011;11:13. doi:10.1186/1472-6823-11-13. PMID: 21736747.
- 11) Draznin B, **Wang C**, Adochio R, Leitner JW, Cornier M-A. Effect of dietary macronutrient composition on AMPK and SIRT1 expression and activity in human skeletal muscle. *Horm Metab Res* 2012;44(09):650-655. PMID 22674476.
- 12) Reusch JEB, **Wang CC**. Type 2 Diabetes in the Federal Health Care Setting: Optimizing Patient Outcomes in Diabetes Management. Article 2: Management of comorbidities and risk factors including hypoglycemia. *Fed Pract* 2012;29(Suppl. 1):8S-13S.
- 13) Hsia E, Seggelke S, Gibbs J, Hawkins RM, Cohlma E, Rasouli N, **Wang C**, Kam I, Draznin B. Subcutaneous Administration of Glargine to Diabetic Patients Receiving Insulin Infusion Prevents Rebound Hyperglycemia. *J Clin Endocrinol Metab* 2012;97(9):3132-3137. PMID 22685233.
- 14) Rasouli N, Seggelke S, Hawkins RM, Gibbs J, Casciano ML, Cohlma E, Taylor-Cousar J, **Wang C**, Pereira R, Hsia E, Draznin B. Cystic fibrosis-related diabetes: inpatient management of 121 patients during 410 admissions. *J Diab Sci Technol* 2012;6(5):1038-1044. PMID: 23063029.
- 15) **Wang CC**, Reusch JEB. Cardio-Diabetes: Special Considerations for Patients with Diabetes and Cardiovascular Disease. Diabetes and Cardiovascular Disease: Changing the Focus from Glycemic Control to Improving Long Term Survival. *Am J Cardiol* 2012;110(9 Suppl):58B-68B. PMID: 23062569.
- 16) **Wang CC**, Adochio R, Leitner JW, Abeyta I, Draznin B, Cornier MA. Effects of a high fat, low carbohydrate versus a low fat, high carbohydrate hypocaloric diet on skeletal muscle insulin signalling in obese individuals. *Metabolism* 2013;62(4):595-603. PMID: 23174405.

- 17) **Low Wang CC**, Xu Y, Lu L, Leitner JW, Gunter J, Sarraf M, Draznin B, Greyson CR, Reusch JEB, Schwartz GG. Arterial insulin resistance in Yucatan micropigs with diet-induced obesity and metabolic syndrome. *J Diabetes Complic* 2013;27(4):307-15. <http://dx.doi.org/10.1016/j.jdiacomp.2013.02.009>. PMID: 23558108.
- 18) **Low Wang CC**, Draznin B. Practical Approach to Management of Inpatient Hyperglycemia Management in Selected Populations. *Hosp Pract (1995)*. 2013;41(2):45-53. doi: 10.3810/hp.2013.04.1025. PMID: 23680736.
- 19) **Wang CCL**, Draznin B. Insulin use in hospitalized patients with diabetes: Navigate with care. *Diabetes Spect* 2013; 26(2):124-130. <http://dx.doi.org/10.2337/diaspect.26.2.124>
- 20) Draznin B, Gilden J, Golden SH, and Inzucchi SE for the PRIDE investigators: Baldwin D, Bode BW, Boord JB, Braithwaite SS, Cagliero E, Draznin B, Dungan KM, Falciglia M, Figaro MK, Gilden J, Golden SH, Hirsch IB, Klonoff D, Korytkowski MT, Kosiborod M, Lien LF, Magee MF, Masharani U, Maynard G, McDonnell ME, Moghissi ES, Rasouli N, Rubin DJ, Rushakoff RJ, Sadhu AR, Schwartz S, Seley JJ, Umpierrez GE, Vigersky RA, **Low CC**, Wexler DJ. Pathways to Quality Inpatient Management of Hyperglycemia and Diabetes: A Call to Action. *Diabetes Care* 2013;36:1807-1814. PMID: 23801791.
- 21) Seggelke SA, Hawkins RM, Gibbs J, Rasouli N, **Wang CC**, Draznin B. Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes. *Endocr Pract* 2014;20(6):536-9. doi: 10.4158/EP13404.OR. PMID: 24326004.
- 22) Seggelke SA, Hawkins RM, Gibbs J, Rasouli N, **Wang C**, Draznin B. Transitional Care Clinic for Uninsured and Medicaid covered Patients with Diabetes Discharged from the Hospital May Reduce Re-admissions: A Pilot Quality Improvement Study. *Hosp Pract (1995)* 2014;42(1):46-51. doi: 10.3810/hp.2014.02.1091. PMID: 24566596.
- 23) Draznin B, Wang Y, Seggelke S, Hawkins RM, Gibbs J, Bridenstine M, Rasouli N, **Wang CL**. Glycemic control and outcomes of hospitalization in noncritically ill patients with type 2 diabetes admitted with cardiac problems or infections. *Endocr Pract* 2014 Dec;20(12):1303-8. doi: 10.4158/EP14174.OR. PMID: 25100383.
- 24) **Low Wang CC**, Galinkin JL, Hiatt WR. Toxicity of a novel therapeutic agent targeting mitochondrial complex I. *Clin Pharmacol Ther* 2015;98(5):551-559. doi: 10.1002/cpt.178. PMID: 26108785.
- 25) Pereira RI, **Low Wang CC**, Wolfe P, Havranek EP, Long CS, Bessesen DH. Associations of adiponectin with adiposity, insulin sensitivity, and diet in young, healthy, Mexican Americans and non-Latino white adults. *Int J Envir Res Public Health* 2015;13(1):ijerph13010054. doi: 10.3390/ijerph13010054. PMID: 2670368.

- 26) Jensen T, **Low Wang CC**. Double trouble: A case of primary hyperparathyroidism and humoral hypercalcemia of malignancy secondary to epithelioid angiosarcoma occurring in a single patient. *AACE Clinical Case Reports* 2016, Vol. 2, No. 2, pp. e146-e150. doi: <http://dx.doi.org/10.4158/EP15768.CR>.
- 27) **Low Wang CC**, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. *Circulation* 2016;133(24):2459-2502. doi: 10.1161/CIRCULATIONAHA.116.022194. PMID: 27297342.
- 28) Wallia A, Umpierrez GE, Nasraway SA, Klonoff DC; PRIDE Investigators. Round Table Discussion on Inpatient Use of Continuous Glucose Monitoring at the International Hospital Diabetes Meeting. *J Diabetes Sci Technol* 2016;10(5):1174-1181. doi: 10.1177/1932296816656380. PMID: 27286715.
- 29) Wang YJ, Seggelke S, Hawkins RM, Gibbs J, Lindsay M, Hazlett I, **Low Wang CC**, Rasouli N, Young KA, Draznin B. Impact of Glucose Management Team on Outcomes of Hospitalization in Patients with Type 2 Diabetes Admitted to the Medical Service. *Endocr Pract* 2016;22(12):1401-1405. PMID: 27540884.
- 30) Seggelke SA, Lindsay MC, Hazlett I, Sanagorski R, Eckel RH, **Low Wang CC**. Cardiovascular safety of antidiabetic drugs in the hospital setting. *Curr Diab Rep* 2017; 17:64. PMID: 28699089.
- 31) Hess CN, **Low Wang CC**, Hiatt WR. PCSK9-inhibitors: Mechanisms of action, metabolic effects, and clinical outcomes. *Ann Rev Med* 2018;69:133-145. PMID: 29095667.
- 32) Rogers RK, Hiatt WR, Patel MR, Shishehbor MH, White R, Khan ND, Bhalla NP, Jones WS, **Low Wang CC**. Ticagrelor in Peripheral Artery Disease Endovascular Revascularization: Challenges in Clinical Trial Execution. *Vascular Med* 2018;23(6):513-522. PMID: 29629845.
- 33) **Low Wang CC**, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Lopes RD, Olin JW, Rockhold FW, Mahaffey KW, Patel MR, and Hiatt WR, on behalf of the EUCLID Trial Executive Committee and Investigators. Cardiovascular and Limb Outcomes in Patients with Diabetes and Peripheral Artery Disease: the EUCLID Trial. *J Am Coll Cardiol* 2018;72(25):3274-3284. PMID: 30573030.
- 34) **Low Wang CC**, Everett BM, Burman KD, Wilson PWF. Cardiovascular safety trials for all new diabetes mellitus drugs? Ten years of FDA guidance requirements to evaluate cardiovascular risk. *Circulation* 2019;139:1741-1743. PMID: 30933621.
- 35) Shubrook JH, Ramirez BF, Healy AM, Salzberg L, Ahmed S, Feinberg H, Schutta M, Schwartz FL, **Low Wang CC**. Primary Care Diabetes Fellowship Programs: Developing National Standards. *Clin Diabetes* 2020. Online ahead of print, Sep 29, 2020. <https://doi.org/10.2337/cd20-0055>.
- 36) Seggelke SA, Ingram CI, Crawley S, **Low Wang CC**. Insulin Resistance in a Hospitalized COVID-19 Patient: A Case Review. *Clin Diabetes* published online Dec 22, 2020. <https://doi.org/10.2337/cd20-0036>.

- 37) Draznin B, Sadhu A, Schutta M, Ramirez BF, Polsky S, Shubrook JH, **Low Wang CC**. The Diabetes Epidemic and Diabetes Fellowships for Primary Care Physicians. *Endocr Pract* 2021 Mar 20;S1530-891X(21)00102-6. doi: 10.1016/j.eprac.2021.03.007. Online ahead of print.

### Books

- 1) Draznin B (ed.), **Low Wang CC** (associate editor) and Rubin D (associate editor). *Diabetes Case Studies: Real Problems, Practical Solutions*. American Diabetes Association, Inc. Alexandria, VA. 2015.
- 2) **Low Wang CC** and Shah A (co-editors). *Medical Management of Type 1 Diabetes*, 7th edition. American Diabetes Association, Inc. Alexandria, VA. 2017.

### Book Chapters

- 1) ' Jones RE, **Wang CCL**. Ch. 31 Adrenal insufficiency. *In Endocrine Secrets*, 4<sup>th</sup> edition, 2005. (ed.) McDermott MT. Elsevier Mosby, Philadelphia.
- 2) ' **Wang CCL**. Chapter 12. Insulin resistance and cardiovascular disease. *In Insulin Resistance and Metabolic Syndrome: Childhood Precursors and Adult Disease from the Contemporary Endocrinology Series*, 2008. Humana Press, New Jersey
- 3) ' **Wang CCL**, Grotzke M, Jones RE. Ch. 30: Adrenal insufficiency. *In Endocrine Secrets*, 5<sup>th</sup> edition, 2009. (ed.) McDermott MT. Mosby Elsevier, Philadelphia.
- 4) ' Schroeder E, **Wang CCL**. Ch. 30: Adrenal insufficiency. *In Endocrine Secrets*, 6<sup>th</sup> edition, 2013. (ed.) McDermott MT. Saunders, Philadelphia.
- 5) ' **Low Wang CC**. Case 15: Type 1 Diabetes versus LADA in a Patient Misdiagnosed with Type 2 Diabetes. *In Diabetes Case Studies: Real Problems, Practical Solutions*. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association, 2015, pp. 58-60.
- 6) ' **Low Wang CC**, Hawkins RM, Gianchandani R, Dungan K. Chapter 6: Glycemic control in the setting of Parenteral Nutrition or Enteral Nutrition Via Tube Feeding. *In: Managing Diabetes and Hyperglycemia in the Hospital Setting: A Clinician's Guide*. American Diabetes Association, Inc. Alexandria, VA. 2016.
- 7) ' Lien L, **Low Wang CC**, Kreider KE, Baldwin D. Chapter 8: Transitioning from intravenous to Subcutaneous insulin. *In Managing Diabetes and Hyperglycemia in the Hospital Setting: A Clinician's Guide*. American Diabetes Association, Inc. Alexandria, VA, 2016.
- 8) ' Rushakoff R, **Low Wang CC**, Seley J, Warnock A. Chapter 29: Resident Education. *In: Managing Diabetes and Hyperglycemia in the Hospital Setting: A Clinician's Guide*. American Diabetes Association, Inc. Alexandria, VA. 2016.

- 9) ' **Low Wang CC**, Galinkin JL, Hiatt WR. Chapter 38: Lessons Learned from a Phase I Clinical Trial of Mitochondrial Complex I Inhibition. *In: Mitochondrial Dysfunction by Drug and Environmental Toxicants*. (eds) Yvonne Will and James A. Dykens. John Wiley & Sons, Inc. Hoboken, NJ. 2018.
- 10) **Low Wang CC**, Draznin B. Part II. Chapter 2. Insulin resistance: Molecular Biology and Pathophysiology. *In Atypical Diabetes: Pathophysiology, Clinical Presentations, and Treatment Options*. American Diabetes Association, Inc. Arlington, VA. 2018.
- 11) Zaman A, **Low Wang CC**. Chapter 1: Diabetes Mellitus: Etiology, Classification, and Diagnosis. *In Endocrine Secrets*, 7<sup>th</sup> edition. Elsevier, Inc., St. Louis, MO. 2019. (ed.) McDermott MT.
- 12) **Low Wang CC**, Zaman A. Chapter 2: Diabetes Mellitus: Acute and Chronic Complications. *In Endocrine Secrets*, 7<sup>th</sup> edition. Elsevier, Inc., St. Louis, MO. 2019. (ed.) McDermott MT.
- 13) Zaman A, **Low Wang CC**. Chapter 5: Diabetes Technology: Pumps, Sensors and Beyond. *In Endocrine Secrets*, 7<sup>th</sup> edition. Elsevier, Inc., St. Louis, MO. 2019. (ed.) McDermott MT.
- 14) Schroeder E, **Low Wang CC**. Ch. 36: Adrenal insufficiency. *In Endocrine Secrets*, 7<sup>th</sup> edition, Elsevier, Inc., St. Louis, MO. 2019. (ed.) McDermott MT.

#### Editorials and Commentaries

- 1) ' Draznin B, Gilden J, Golden SH, Inzucchi S; PRIDE Investigators. Response to comment on: Draznin et al. Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action. *Diabetes Care* 2013;36(12):e220. doi: 10.2337/dc13-1855. PMID: 24265389.
- 2) ' **Low Wang CC**, Draznin B. Use of NPH Insulin for Glucocorticoid-Induced Hyperglycemia. *Endocr Pract* 2016;22(2):271-273. doi: 10.4158/EP151101.CO. PMID: 26789338.
- 3) ' **Low Wang CC**, Michels AW. The Missing Link for Cardiovascular Disease in Type 1 Diabetes Mellitus? Hyperglycemia-induced Cardiac Autoimmunity. Expert Analysis for American College of Cardiology website: Diabetes and Cardiometabolic Disease Clinical Topic Collection. <http://www.acc.org>. Jul 25, 2019. Accessed Aug 23, 2019. Available at: <https://www.acc.org/latest-in-cardiology/articles/2019/07/25/10/49/the-missing-link-for-cardiovascular-disease-in-type-1-diabetes-mellitus>.

#### Other

- 1) ' **Wang CC**, Wierman ME. Positron emission tomography scanning for ectopic Cushing's Syndrome. *EndoTrends* 2003;10(1):6-9.
- 2) ' **Low Wang CC** and Draznin B. Inpatient Management of Patients with Diabetes. *First Consult, MD Consult* Web site available at [www.mdconsult.com](http://www.mdconsult.com). Posted September 11, 2013. Accessed September 11, 2013.
- 3) ' **Low Wang CC**. Diabetes and immunizations. *Physicians' Weekly*. 2014. <http://www.physiciansweekly.com/keeping-up-vaccinations-people-with-diabetes/>
- 4) ' **Low Wang CC**. Diabetic neuropathy. *Physicians' Weekly*. 2014. <http://www.physiciansweekly.com/taking-proactive-approach-diabetic-neuropathy/>



- 5) ' **Low Wang CC**. Diabetes and Cardiovascular Disease. *Physicians' Weekly*. 2015.  
<http://www.physiciansweekly.com/cme-cardiometabolic-risk-type-2-diabetes-heart-disease/>
- 6) ' **Low Wang CC**. Syllabus. Inpatient Hyperglycemia. *Endocrine Society Meet the Professor Handbook*. 2017.
- 7) ' **Low Wang CC**. Commentary for [www.PracticeUpdate.com](http://www.PracticeUpdate.com) on *Diabetes Care* article: The Presence of Diabetes and Higher HbA1c Are Independently Associated With Adverse Outcomes After Surgery. Available at: <https://www.practiceupdate.com/content/diabetes-and-higher-hba1c-levels-are-independently-associated-with-adverse-postsurgical-outcomes/66074/62>. Accessed September 7, 2018.
- 8) ' **Low Wang CC**. Commentary for [www.PracticeUpdate.com](http://www.PracticeUpdate.com) on *Lancet Diabetes and Endocrinology* article: Association of Preoperative Glucose Concentration With Myocardial Injury and Death After Non-ardiac Surgery (GlucoVISION): A Prospective Cohort Study. Available at: <http://www.practiceupdate.com/content/association-of-preoperative-glucose-concentration-with-myocardial-injury-and-death-after-noncardiac-surgery/71372/65/8/1>. Accessed August 15, 2018.
- 9) ' **Low Wang CC**. Commentary for [www.PracticeUpdate.com](http://www.PracticeUpdate.com) on *Diabetes Care* article: A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/comparing-glargine-u300-and-glargine-u100-for-the-inpatient-management-of-patients-with-type-2-diabetes/98993/65/8/1>. Accessed April 29, 2020
- 10) **Low Wang CC**. Diabetes: Nutrition and Sugar. Extended Interview (running time: 0:38:00) by Ambrose Digital Streaming Video. <https://www.ambrosevideo.com/screening-room/163-dnx>
- 11) **Low Wang CC**, McRae M. Liraglutide Hospital Discharge Trial: A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide versus Glargine Insulin for the Management of Patients with Type 2 Diabetes After Hospital Discharge. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/liraglutide-hospital-discharge-trial/114021/65/8/1>. Accessed March 12, 2021.

### Selected Abstracts

- 1) ' **Low CC**, King CL, Klion A, Nutman TB. Cytokine Production in Patients with Helminth Infection in Relation to IgE Synthesis. NIAID Summer Student Program Poster Session 1990. Poster.
- 2) ' **Low CC**, Ilgen C, King CL. Cytokine Production as related to IgE Synthesis in Patients with Helminth Infection. EUREKA National Conference on Undergraduate Research 1991. Poster.
- 3) ' Langsam AL, **Low CC**, Madden KS, Felten SY, Felten DL, Bellinger DL. The Effect of Chemical Sympathectomy on Primary Antibody Response in Young and Old F344 Rats. Society for Neurosciences Abstracts 1993;19:944(388.1).
- 4) ' **Low CC**, Gumbiner B. Monounsaturated Fatty Acids Potentiate the Metabolic Effects of Dieting in Obese NIDDM. *Journal of Investigative Medicine* 1995;42(1)Suppl.1:135A.
- 5) ' **Low CC**, Gumbiner B. Increased Insulin Secretion and Improved Glycemic Control by High Monounsaturated Fatty Acid (MUFA) vs. High Carbohydrate (CHO) Hypocaloric Diet in Obese Noninsulin-Dependent Diabetes Mellitus. *Diabetes* 1995;44(Suppl. 1):8A, Abstract 21.

- 6) ' Grossman EB, **Low CC**, Gumbiner B. Differential Effects of Monounsaturated Fat (MUFA) and High Carbohydrate-Induced Weight Loss on Insulin and Blood Pressure (BP). *Journal of the American Society of Nephrology* 1995;6(3):641, Abstract 772.
- 7) ' **Wang CCL**, Draznin B. Phenotypic Modulation of Vascular Smooth Muscle Cells by Insulin: The Role of Phosphatidylinositol 3-kinase. *J Investig Med* 2002;50(1):51A, Abstract 277.
- 8) ' **Wang CCL**, Draznin B. Phosphatidylinositol 3-kinase Modulates the Effect of Insulin on Vascular Smooth Cell Phenotype. *Diabetes* 2002;51(Supp. 2):A181, Abstract 732.
- 9) ' **Wang CCL**, Golovchenko I, Draznin B. Vascular Smooth Muscle Cell Quiescence and Migration Are Mediated Differentially Via Phosphatidylinositol 3-Kinase- and Mitogen-Activated Kinase-Dependent Pathways. *J Investig Med* 2003;51 Supp.1:S162, Abstract 403.
- 10) **Wang CCL**, Golovchenko I, Draznin B. Vascular smooth muscle cell quiescence and migration are mediated differentially via phosphatidylinositol 3-kinase- and mitogen-activated kinase-dependent pathways. *Diabetes/Metabolism Research and Reviews* 2003;19(2):S5, 2774.
- 11) **Wang CCL**, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell quiescence and migration via distinct signaling pathways. *Diabetes* 2003;52(Supp.1):A182, 780-P.
- 12) **Wang CCL**, Draznin B. Insulin and oxidative stress have additive effects on Egr-1 in vascular smooth muscle cells. Endocrine Society Annual Meeting Abstract Book 2004, poster 1-89.
- 13) **Wang CCL**, Draznin B. Signaling pathways mediating the effects of insulin and oxidative stress on Egr-1 expression in vascular smooth muscle cells. Keystone Symposium: The Cellular Biology of Atherosclerosis 2005, poster 320.
- 14) **Wang CCL**, Draznin B. Insulin and oxidant stress effects on early growth response gene-1 expression are mediated differently in vascular smooth muscle cells. *J Investig Med* 2005;53 Supp.1:S105, Abstract 159.
- 15) **Wang CCL**, Sorribas V, Sharma G, Levi M, Draznin B. Insulin-mediated increase in vascular smooth muscle cell phosphate transport may be associated with vascular calcification in insulin resistance. *Diabetes* 2005;54(Supp.1):A192, 783-P.
- 16) **Wang CCL**, Sorribas V, Sharma G, Levi M, Draznin B. Insulin attenuates VSMC calcification but increases VSMC phosphate transport. Keystone Symposium: Metabolic Syndrome and Cardiovascular Risk 2007, poster 340.
- 17) **Wang CCL**, Draznin B, Leitner JW, Jorgenson S, Lu L, Ya X, Greyson C, Schwartz G, Reusch JEB. Aortic insulin signaling is perturbed in a large animal model of diet-induced obesity. *J Investig Med* 2008;56(1):190, Abstract 262.

- 18) **Wang CCL**, Draznin B, Leitner JW, Jorgensen S, Lu L, Xu Y, Greyson CR, Reusch JE, Schwartz GG. Disruption of insulin signaling in a large animal model of diet-induced obesity. *Diabetes* 2008;57(Supp.1):A475,1709-P.
- 19) Schwartz GG, Draznin B, Reusch JEB, Leitner JW, Lu L, Xu Y, Greyson CR, **Wang CCL**. Insulin-stimulated PI 3-kinase activity is blunted, but Akt phosphorylation is preserved in aortas of pigs with diet-induced obesity. *J Am Coll Cardiol* 2009;53(10,Supp. 1):A435. Poster 1031-102.
- 20) **Wang CCL**, Pereira RI, Benton K, Dickinson M, Estacio R, Krantz M, Neuman C, Long C, Havranek E, Chonchol M. Association between 25-hydroxyvitamin D levels and insulin resistance in hypertensive subjects. *14<sup>th</sup> Workshop on Vitamin D* abstract book 2009.
- 21) **Wang CCL**, Pereira RI, Benton KL, Dickinson LM, Estacio RO, Krantz MJ, Neuman C, Long CS, Havranek E and Chonchol MB. Vitamin D levels and insulin resistance in a mostly Latino hypertensive cohort. *J Am Soc Nephrol Abstracts* Issue 20:2009, p 644A. SA-PO2335.
- 22) **Wang CCL**, Lu L, Xu Y, Greyson C, Jacobs S, Reusch JEB, Gianani R, Draznin B, Schwartz G. Diet-induced insulin resistance causes isoform-specific abnormalities of Akt signaling in arterial wall of pigs. *Circulation* 2009;120(18 Supp): S443-S444, Abstract 1087.
- 23) **Wang CCL**, Gunter J, Leitner JW, Lu L, Xu Y, Greyson C, Gianani R, Draznin B, Reusch JEB, Schwartz GG. Early defects occur in PI3-kinase/Akt signaling and vascular function in a novel porcine model of diet-induced obesity. *Diabetes* 2010;59(Supp 1):A66, oral presentation 249-OR.
- 24) **Wang CCL**, Pereira RI, Hosokawa P, Dickinson LM, Krantz M, Neuman C, Long C, Chonchol M, Havranek E. Association between 25-hydroxyvitamin D and adiponectin levels in hypertensive subjects. *Diabetes* 2010;59(Supp 1):A225, poster 828-P.
- 25) **Wang CCL**, Xu Y, Leitner JW, Lu L, Draznin B, Greyson C, Reusch JEB, Schwartz GG. Blunted Vascular PI3-Kinase Signaling in a Novel Porcine Model of Diet-Induced Obesity Is Due to Increased Total P85alpha and Is Accompanied by Vascular Dysfunction. *Endocr Rev* 2011;32(03\_MeetingAbstracts):P3-377.
- 26) **Wang CCL**, Seggelke S, Hawkins RM, Cohlmiä E, Gibbs J, Rasouli N, and Draznin B. Transitional Care Clinic for Patients with Diabetes May Prevent Re-Hospitalizations. *Diabetes* 2013;July supplement. 1217-P. Selected for Guided Audio Poster Tour.
- 27) Seggelke S, Hawkins RM, Gibbs J, Cohlmiä E, Rasouli N, **Wang CCL**, and Draznin B. Effects of Glargine Insulin Delivery Method (Pen-Device vs. Vial-Syringes) on Glycemic Control and Patient Preferences. *Diabetes* 2013;July supplement. 988-P.
- 28) Schauer I\*, **Wang CCL\***, Bridenstine M, Durbin R, Herlache L, Regensteiner J and Reusch JEB. Rosiglitazone improves C-reactive protein and liver function in impaired glucose tolerance but not

coronary artery calcification or exercise function. *Diabetes* 2013;July supplement. 2337-PO.

\*indicates co-first author

- 29) Wang YJ, Hawkins RM, Seggelke S, Gibbs J, **Wang CCL**, Draznin B. Optimal Glycemic Control Improves Clinical Outcomes in Patients with Type 2 Diabetes. *Diabetes* 2013;July supplement. 86-LB.
- 30) Jensen T, **Low Wang CC**. Double trouble: A case of primary hyperparathyroidism and humoral hypercalcemia of malignancy. *Endocr Rev* 2014;35(3 Suppl), poster SAT-0202.
- 31) Schwartz GG, Leitner JW, Lu L, Ye S, Pendyal A, Pereira R, **Wang CC**, Reusch JE, Greyson CR. Depot-specific abnormalities in adipose tissue insulin signaling in a porcine model of metabolic syndrome. In Core 2. Epidemiology and Prevention of CV Disease: Physiology, Pharmacology and Lifestyle - Session Title: Diabetes Mellitus and CVD: Prevention and Management V. *Circulation* 2014;130(Supplement 2), A12109.
- 32) **Low Wang CC**, Anderson M. Targeting gaps in hospital management of diabetes and stress hyperglycemia with resident education. 2015 University of Colorado Education Innovation Symposium.
- 33) **Low Wang CC**, Sanagorski R, Hawkins RM, Gibbs J, Tompkins K, Bridenstine M, Seggelke S, Draznin B. Impact of Subcutaneous Detemir Insulin on Rebound Hyperglycemia in Hospitalized Patients with Diabetes Transitioning From a Continuous Intravenous Insulin Infusion. Endocrine Society Annual Meeting 2015. Poster Preview PP01-2. Poster number THR-662.
- 34) Thompson E, Everhart B, **Low Wang C**. Reduction of Hyperglycemia on a Medical Unit Using a Focused, Multi-Disciplinary Partnership. University of Colorado Health Research Symposium 2017.
- 35) Blomster JL, **Low Wang CC**, Heizer G, Berger JS, Baumgartner I, Fowkes GR, Held P, Katona BG, Norgren L, Jones WS, Rockhold FW, Mahaffey KW, Patel MR, Hiatt WR on behalf of the EUCLID Trial Executive Committee and Investigators. Diabetes and Cardiovascular Risk in Patients with Symptomatic Peripheral Artery Disease. European Society of Cardiology Congress 2017. *Eur Heart J* 2017;38(Supplement):1080. Poster session 6: Vascular diseases -2; Peripheral artery disease – pathophysiology, epidemiology, diagnosis. P5193.
- 36) Keshawarz A, Alman A, **Low Wang CC**, Mitchell S, Schauer IE, Reusch JEB, Regensteiner JG, Snell-Bergeon JK. Visceral and subcutaneous adipose tissue attenuation differs by type 1 and type 2 diabetes status. American Diabetes Association 79<sup>th</sup> Scientific Sessions. *Diabetes* 2019;68(Supplement 1): 1471-P. <https://doi.org/10.2337/db19-1471-P>.
- 37) Behan S, **Low Wang CC**, Hess C, Mulder H, Gutierrez A, Fowkes F, Baumgartner I, Berger J, Katona B, Mahaffey K, Norgren L, Blomster J, Jones S, Patel MR, Hiatt WR, Bonaca MP. Polyvascular disease with and without diabetes and the risk of adverse cardiovascular and limb events in the EUCLID trial. *J Am Coll Cardiol* 2020. 40. Vascular medicine: Non coronary arterial disease. 20-A-14515-ACC.

- 38) Mayson SE, Haugen B, **Low Wang CC**. The Endocrinology Fellowship Thyroid/Neck Ultrasound Curriculum Innovations Project. 2020 AME Education Symposium. University of Colorado Anschutz Medical Campus, Aurora, CO.
- 39) Zaman A, McDermott MT, Mansfield V, **Low Wang CC**. Mortality in Patients with Glucose Derangements after ICU Admission. American Diabetes Association's 80th Scientific Sessions 2020 Virtual. 1611-P in category 16-F Epidemiology—Other.
- 40) Govsyeyev N, Nehler MR, **Low Wang CC**, Kavanagh S, Hiatt WR, Long C, Jones WS, Fowkes FG, Berger JS, Patel MR, Katona B, Norgren L and Bonaca MP. Amputation in Patients With PAD With and Without Diabetes: Insights From the EUCLID Trial. American Heart Association Scientific Sessions 2020 Virtual. *Circulation* 2020;142(Suppl\_3):Abstract 16512.
- 41) Hawkins RM, Seggelke S, Gibbs J, Lindsay M, **Low Wang CC**. Glycemic Control in Hospitalized Patients Receiving Enteral Nutrition. American Diabetes Association 81<sup>st</sup> Scientific Sessions 2021 (virtual). Poster #2021-A-5827-Diabetes. *Diabetes* (in press).
- 42) **Low Wang CC**, Nehler M, Lloyd Haskell, Scott D Berkowitz, E. Sebastian Debus, Rupert Bauersachs, Marc P Bonaca. Risk Profile of Comorbid Diabetes and Benefit of Rivaroxaban in Patients with Critical Limb Ischemia: Insights from VOYAGER PAD. American Diabetes Association 81<sup>st</sup> Scientific Sessions 2021 (virtual). Poster #2021-LB-6784-Diabetes. *Diabetes* (in press).